Novo Nordisk Stock News

Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth ​up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are ‌traditionally treated with injectable drugs.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value...

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.

Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up ​discovery and development of new medicines, the ‌companies said on Wednesday.

The companies said their collaboration aims to address key challenges in the drug-discovery process by developing targeted solutions and workflows.

Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, ​as the Wegovy maker seeks to regain ground ‌in the fast-growing obesity drug market.

Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach ​to company culture as it looks ‌to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.